AstraZeneca (LON:AZN) Earns "Buy" Rating from Shore Capital

Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN - Free Report) in a report published on Friday morning, Marketbeat reports.

Other equities analysts also recently issued research reports about the company. JPMorgan Chase & Co. reiterated an "overweight" rating on shares of AstraZeneca in a report on Wednesday, February 19th. Berenberg Bank reiterated a "buy" rating and set a GBX 140 ($1.81) price target on shares of AstraZeneca in a report on Monday, January 27th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of GBX 7,542.80 ($97.50).

AstraZeneca Stock Performance

AZN stock traded up GBX 44 ($0.57) during midday trading on Friday, hitting £120.72 ($156.05). 3,148,518 shares of the company traded hands, compared to its average volume of 20,631,598. AstraZeneca has a twelve month low of GBX 9,670 ($125.00) and a twelve month high of £133.88 ($173.06). The company has a quick ratio of 0.59, a current ratio of 0.93 and a debt-to-equity ratio of 73.83. The business has a 50 day simple moving average of £113.08 and a 200-day simple moving average of £114.10. The stock has a market capitalization of £232.27 billion, a price-to-earnings ratio of 33.09, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.